(COLL) Collegium Pharmaceutical - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US19459J1043
Stock: Stimulant, Buprenorphine Film, Oxycodone, Tapentadol, Naldemedine
Total Rating 59
Risk 76
Buy Signal -0.50
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 39.2% |
| Relative Tail Risk | -6.23% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.20 |
| Alpha | 42.70 |
| Character TTM | |
|---|---|
| Beta | 0.498 |
| Beta Downside | 0.569 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.07% |
| CAGR/Max DD | 0.51 |
Description: COLL Collegium Pharmaceutical January 20, 2026
Collegium Pharmaceutical Inc. (NASDAQ: COLL) is a specialty pharma focused on pain-management and related central-nervous-system therapies. Its current product suite includes Jornay PM (methylphenidate for ADHD), Belbuca (buccal buprenorphine for chronic severe pain), Xtampza ER (abuse-deterrent extended-release oxycodone), Nucynta ER/IR (tapentadol for acute and persistent pain), and Symproic (naldemedine for opioid-induced constipation).
As of its latest 2023 filing, COLl reported net revenue of roughly $617 million, with Xtampza ER and Belbuca contributing the bulk of growth amid a $15 billion U.S. ADHD market and a $30 billion chronic pain market that is increasingly regulated for opioid safety. The company’s pipeline includes a Phase III buprenorphine-based formulation targeting opioid-use-disorder, and its earnings are sensitive to FDA labeling changes and payer reimbursement trends, which have historically driven 5-10 % quarterly revenue volatility in the pain-therapy segment.
If you want a data-rich, side-by-side comparison of COLl’s valuation multiples and risk profile, ValueRay’s analyst toolkit offers a concise next step for deeper research.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 58.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 6.23 > 1.0 |
| NWC/Revenue: 21.26% < 20% (prev -2.61%; Δ 23.86% < -1%) |
| CFO/TA 0.18 > 3% & CFO 290.9m > Net Income 58.4m |
| Net Debt (766.3m) to EBITDA (392.7m): 1.95 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.4m) vs 12m ago -1.80% < -2% |
| Gross Margin: 57.22% > 18% (prev 0.62%; Δ 5659 % > 0.5%) |
| Asset Turnover: 46.70% > 50% (prev 36.65%; Δ 10.05% > 0%) |
| Interest Coverage Ratio: 1.94 > 6 (EBITDA TTM 392.7m / Interest Expense TTM 85.7m) |
Altman Z'' 1.01
| A: 0.10 (Total Current Assets 613.9m - Total Current Liabilities 452.9m) / Total Assets 1.61b |
| B: -0.07 (Retained Earnings -118.1m / Total Assets 1.61b) |
| C: 0.10 (EBIT TTM 166.5m / Avg Total Assets 1.62b) |
| D: -0.09 (Book Value of Equity -117.8m / Total Liabilities 1.33b) |
| Altman-Z'' Score: 1.01 = BB |
Beneish M -3.15
| DSRI: 0.81 (Receivables 233.9m/228.5m, Revenue 757.1m/599.2m) |
| GMI: 1.09 (GM 57.22% / 62.36%) |
| AQI: 0.85 (AQ_t 0.61 / AQ_t-1 0.72) |
| SGI: 1.26 (Revenue 757.1m / 599.2m) |
| TATA: -0.14 (NI 58.4m - CFO 290.9m) / TA 1.61b) |
| Beneish M-Score: -3.15 (Cap -4..+1) = AA |
What is the price of COLL shares?
As of February 06, 2026, the stock is trading at USD 46.92 with a total of 416,797 shares traded.
Over the past week, the price has changed by +3.46%, over one month by +2.71%, over three months by +30.88% and over the past year by +52.78%.
Over the past week, the price has changed by +3.46%, over one month by +2.71%, over three months by +30.88% and over the past year by +52.78%.
Is COLL a buy, sell or hold?
Collegium Pharmaceutical has received a consensus analysts rating of 4.20.
Therefore, it is recommended to buy COLL.
- StrongBuy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the COLL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.2 | 13.3% |
| Analysts Target Price | 53.2 | 13.3% |
| ValueRay Target Price | 57.3 | 22.2% |
COLL Fundamental Data Overview February 03, 2026
P/E Trailing = 27.8303
P/E Forward = 6.105
P/S = 1.9174
P/B = 5.2166
Revenue TTM = 757.1m USD
EBIT TTM = 166.5m USD
EBITDA TTM = 392.7m USD
Long Term Debt = 743.5m USD (from longTermDebt, last quarter)
Short Term Debt = 66.0m USD (from shortTermDebt, last quarter)
Debt = 936.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 766.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.08b USD (1.45b + Debt 936.3m - CCE 305.7m)
Interest Coverage Ratio = 1.94 (Ebit TTM 166.5m / Interest Expense TTM 85.7m)
EV/FCF = 7.20x (Enterprise Value 2.08b / FCF TTM 289.3m)
FCF Yield = 13.89% (FCF TTM 289.3m / Enterprise Value 2.08b)
FCF Margin = 38.21% (FCF TTM 289.3m / Revenue TTM 757.1m)
Net Margin = 7.72% (Net Income TTM 58.4m / Revenue TTM 757.1m)
Gross Margin = 57.22% ((Revenue TTM 757.1m - Cost of Revenue TTM 323.9m) / Revenue TTM)
Gross Margin QoQ = 61.70% (prev 57.65%)
Tobins Q-Ratio = 1.30 (Enterprise Value 2.08b / Total Assets 1.61b)
Interest Expense / Debt = 2.32% (Interest Expense 21.8m / Debt 936.3m)
Taxrate = 27.46% (11.9m / 43.4m)
NOPAT = 120.8m (EBIT 166.5m * (1 - 27.46%))
Current Ratio = 1.36 (Total Current Assets 613.9m / Total Current Liabilities 452.9m)
Debt / Equity = 3.41 (Debt 936.3m / totalStockholderEquity, last quarter 274.8m)
Debt / EBITDA = 1.95 (Net Debt 766.3m / EBITDA 392.7m)
Debt / FCF = 2.65 (Net Debt 766.3m / FCF TTM 289.3m)
Total Stockholder Equity = 242.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.60% (Net Income 58.4m / Total Assets 1.61b)
RoE = 24.09% (Net Income TTM 58.4m / Total Stockholder Equity 242.6m)
RoCE = 16.89% (EBIT 166.5m / Capital Employed (Equity 242.6m + L.T.Debt 743.5m))
RoIC = 11.26% (NOPAT 120.8m / Invested Capital 1.07b)
WACC = 5.37% (E(1.45b)/V(2.39b) * Re(7.75%) + D(936.3m)/V(2.39b) * Rd(2.32%) * (1-Tc(0.27)))
Discount Rate = 7.75% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.85%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈250.6m ; Y1≈309.1m ; Y5≈526.4m
Fair Price DCF = 460.6 (EV 15.33b - Net Debt 766.3m = Equity 14.56b / Shares 31.6m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 51.59 | EPS CAGR: -14.29% | SUE: -3.51 | # QB: 0
Revenue Correlation: 70.52 | Revenue CAGR: 72.05% | SUE: 4.0 | # QB: 3
EPS next Quarter (2026-03-31): EPS=1.62 | Chg30d=-0.037 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=7.94 | Chg30d=-0.069 | Revisions Net=-1 | Growth EPS=+6.3% | Growth Revenue=+3.4%
P/E Forward = 6.105
P/S = 1.9174
P/B = 5.2166
Revenue TTM = 757.1m USD
EBIT TTM = 166.5m USD
EBITDA TTM = 392.7m USD
Long Term Debt = 743.5m USD (from longTermDebt, last quarter)
Short Term Debt = 66.0m USD (from shortTermDebt, last quarter)
Debt = 936.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 766.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.08b USD (1.45b + Debt 936.3m - CCE 305.7m)
Interest Coverage Ratio = 1.94 (Ebit TTM 166.5m / Interest Expense TTM 85.7m)
EV/FCF = 7.20x (Enterprise Value 2.08b / FCF TTM 289.3m)
FCF Yield = 13.89% (FCF TTM 289.3m / Enterprise Value 2.08b)
FCF Margin = 38.21% (FCF TTM 289.3m / Revenue TTM 757.1m)
Net Margin = 7.72% (Net Income TTM 58.4m / Revenue TTM 757.1m)
Gross Margin = 57.22% ((Revenue TTM 757.1m - Cost of Revenue TTM 323.9m) / Revenue TTM)
Gross Margin QoQ = 61.70% (prev 57.65%)
Tobins Q-Ratio = 1.30 (Enterprise Value 2.08b / Total Assets 1.61b)
Interest Expense / Debt = 2.32% (Interest Expense 21.8m / Debt 936.3m)
Taxrate = 27.46% (11.9m / 43.4m)
NOPAT = 120.8m (EBIT 166.5m * (1 - 27.46%))
Current Ratio = 1.36 (Total Current Assets 613.9m / Total Current Liabilities 452.9m)
Debt / Equity = 3.41 (Debt 936.3m / totalStockholderEquity, last quarter 274.8m)
Debt / EBITDA = 1.95 (Net Debt 766.3m / EBITDA 392.7m)
Debt / FCF = 2.65 (Net Debt 766.3m / FCF TTM 289.3m)
Total Stockholder Equity = 242.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.60% (Net Income 58.4m / Total Assets 1.61b)
RoE = 24.09% (Net Income TTM 58.4m / Total Stockholder Equity 242.6m)
RoCE = 16.89% (EBIT 166.5m / Capital Employed (Equity 242.6m + L.T.Debt 743.5m))
RoIC = 11.26% (NOPAT 120.8m / Invested Capital 1.07b)
WACC = 5.37% (E(1.45b)/V(2.39b) * Re(7.75%) + D(936.3m)/V(2.39b) * Rd(2.32%) * (1-Tc(0.27)))
Discount Rate = 7.75% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.85%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈250.6m ; Y1≈309.1m ; Y5≈526.4m
Fair Price DCF = 460.6 (EV 15.33b - Net Debt 766.3m = Equity 14.56b / Shares 31.6m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 51.59 | EPS CAGR: -14.29% | SUE: -3.51 | # QB: 0
Revenue Correlation: 70.52 | Revenue CAGR: 72.05% | SUE: 4.0 | # QB: 3
EPS next Quarter (2026-03-31): EPS=1.62 | Chg30d=-0.037 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=7.94 | Chg30d=-0.069 | Revisions Net=-1 | Growth EPS=+6.3% | Growth Revenue=+3.4%